Table 1.

Statistically significant findings (p<0.05) of Cochrane systematic reviews for secondary fracture prevention with oral bisphosphonates for postmenopausal women

Treatment	Hip fracture reduction (%)		Vertebral fracture reduction (%)		Non-vertebral fracture reduction (%)		Reference
	RRRa (95% CIc)	ARRb	RRR (95% CI)	ARR	RRR (95% CI)	ARR
Alendronated	53 (15-74)	1	45 (31-57)	6	23 (8-36)	2	Wells et al [11]
Etidronatee	-	-	47 (13-68)	5	-	-	Wells et al [12]
Risedronatef	26 (6-41)	1	39 (24-50)	5	20 (10-28)	2	Wells et al [13]

^aRRR = Relative Risk Reduction

^bARR = Absolute Risk Reduction

^cCI = Confidence Interval

^d10 mg daily dose

^e400 mg daily dose

^f5 mg daily dose